Therapy News and Research

RSS

Cephalon, BDC sign option agreement

Cephalon, Inc. and BioAssets Development Corporation (BDC), a privately held biopharmaceutical company, today announced that the companies have signed an agreement that will provide Cephalon with an option to acquire BDC.

26 Oct 2009

Phase 2a clinical trial in nonsense mutation hemophilia A and hemophilia B initiated

PTC Therapeutics, Inc. (PTC) today announced it is expanding the development of ataluren, an investigational new drug, to a third indication with the initiation of a Phase 2a clinical trial in nonsense mutation hemophilia A (nmHA) and hemophilia B (nmHB).

26 Oct 2009

Results from Phase I dose-escalation study of AT-101 announced

Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).

26 Oct 2009

German based LIFEBRIDGE AG receives FDA clearance for mobile LIFEBRIDGE

German based LIFEBRIDGE AG has received clearance from the U.S. Food and Drug Administration (FDA) for a compact, lightweight, mobile heart-lung machine, a first for any manufacturer worldwide.

26 Oct 2009

Anti-viral drug development programs progress successfully, reports NanoViricides

NanoViricides, Inc. (the "Company"), reports that the Company is well financed and its game changing anti-viral drug development programs are progressing successfully. As such, Management knows of no reason for the recent decline in stock price and associated volatility.

26 Oct 2009

Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals

Napo Pharmaceuticals, Inc. has in-licensed from the University of California Regents additional small-molecule cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor technology including gastrointestinal (GI) and polycystic kidney disease (PKD) indications.

26 Oct 2009

AlterG M300 anti-gravity treadmill for physical therapy clinics, fitness and training facilities

AlterG, Inc., makers of the Anti-Gravity Treadmill, a revolutionary technology for rehabilitation and athletic training, today launched the AlterG M300. The M300 delivers the same anti-gravity technology originally developed at NASA and found in AlterG's P200 series, only at a third of the price and with a sleek new design.

26 Oct 2009

Canadian cardiologists, oncologists team up to fight breast cancer

A team of Canadian cardiologists, in collaboration with oncologists, are playing an important role in the war against breast cancer Dr. Michael McDonald told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

26 Oct 2009

Dr. Dennis Lin retains Adam Kluger Public Relations to promote his psychiatric practice

Adam Kluger Public Relations (www.adamklugerpr.com) announced today that Dr. Dennis Lin, MD (www.drdennismd.com) has retained the New York based boutique PR firm to provide media support and to promote his psychiatric practice which specializes in sexology, sexual relationships, interpersonal difficulties and couples therapy.

26 Oct 2009

San Francisco Business Times ranks VitalWear as one of the fastest-growing private companies in the Bay Area

VitalWear, Inc. (www.vitalwear.com), a leader in thermal therapy medical devices announced that the San Francisco Business Times honored the company as one of the fastest-growing private companies in the Bay Area for 2009. VitalWear was ranked #17 out of 100 companies.

26 Oct 2009

Enzyme Mst3b is essential for regenerating damaged axons in live animal model, say researchers

Researchers at Children's Hospital Boston report that an enzyme known as Mst3b, previously identified in their lab, is essential for regenerating damaged axons (nerve fibers) in a live animal model, in both the peripheral and central nervous systems.

26 Oct 2009

AAO-PAAO meeting discusses tougher challenges of treating premature babies' vision

Highlights of today's Scientific Program of the 2009 American Academy of Ophthalmology (AAO) - Pan-American Association of Ophthalmology (PAAO) Joint Meeting include: John T. Flynn, MD, Columbia University School of Medicine, discussing the ever-tougher challenges Eye M.D.s face in caring for the vision of the tiniest premature babies; and a report by Bradford W. Lee, MD, Stanford University School of Medicine, on barriers to glaucoma follow-up as perceived by patients in an urban, culturally diverse clinic.

26 Oct 2009

Probiotic therapy can be effective for treating intestinal disorders

The probiotic, Bacillus polyfermenticus, can help mice recover from colitis, a new study has found. Mice treated with B. polyfermenticus during the non-inflammatory period of the disease had reduced rectal bleeding, their tissues were less inflamed and they gained more weight than mice that did not receive the treatment.

26 Oct 2009

Aldosterone antagonist therapy can be adopted for treating heart failure

Less than one-third of patients hospitalized for heart failure and participating in a quality improvement registry received a guideline-recommended treatment of heart failure, aldosterone antagonist therapy, according to a study in the October 21 issue of JAMA.

26 Oct 2009

New findings demonstrating pharmacoeconomic benefits of Ceplene released

EpiCept Corporation announces the release of new findings demonstrating the pharmacoeconomic benefits of Ceplene® (histamine dihydrochloride) for the remission maintenance of Acute Myeloid Leukemia (AML) patients in first remission.

26 Oct 2009

Saving sight in premature babies: The past, present and future of ROP treatment

26 Oct 2009

Gene therapy may help improve congenital blindness in children

Born with a retinal disease that made him legally blind, and would eventually leave him totally sightless, the nine-year-old boy used to sit in the back of the classroom, relying on the large print on an electronic screen and assisted by teacher aides. Now, after a single injection of genes that produce light-sensitive pigments in the back of his eye, he sits in front with classmates and participates in class without extra help. In the playground, he joins his classmates in playing his first game of softball.

26 Oct 2009

Orexigen Therapeutics announces new data from COR-I, COR-II and COR-Diabetes trials for Contrave

Orexigen® ( )Therapeutics, Inc today announced new data from the COR-I, COR-II and COR-Diabetes trials for Contrave® (bupropion SR/ naltrexone SR) to expand on top-line results announced in July. Contrave is the first of the Company's two late stage candidates for the treatment of obesity.

26 Oct 2009

Omega-3 fatty acid supplements do not improve levels of depression in heart disease patients

Contrary to the findings of some studies, new research indicates that augmenting antidepressant therapy with an omega-3 fatty acid supplement does not result in improvement in levels of depression in patients with coronary heart disease, according to a study in the October 21 issue of JAMA.

26 Oct 2009

Supplemental oxygen during stroke is effective to combat brain tissue damage

Scientists have countered findings of previous clinical trials by showing that giving supplemental oxygen to animals during a stroke can reduce damage to brain tissue surrounding the clot.

26 Oct 2009

Therapy News and Research

Cephalon, BDC sign option agreement

Phase 2a clinical trial in nonsense mutation hemophilia A and hemophilia B initiated

Results from Phase I dose-escalation study of AT-101 announced

German based LIFEBRIDGE AG receives FDA clearance for mobile LIFEBRIDGE

Anti-viral drug development programs progress successfully, reports NanoViricides

Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals

AlterG M300 anti-gravity treadmill for physical therapy clinics, fitness and training facilities

Canadian cardiologists, oncologists team up to fight breast cancer

Dr. Dennis Lin retains Adam Kluger Public Relations to promote his psychiatric practice

San Francisco Business Times ranks VitalWear as one of the fastest-growing private companies in the Bay Area

Enzyme Mst3b is essential for regenerating damaged axons in live animal model, say researchers

AAO-PAAO meeting discusses tougher challenges of treating premature babies' vision

Probiotic therapy can be effective for treating intestinal disorders

Aldosterone antagonist therapy can be adopted for treating heart failure

New findings demonstrating pharmacoeconomic benefits of Ceplene released

Saving sight in premature babies: The past, present and future of ROP treatment

Gene therapy may help improve congenital blindness in children

Orexigen Therapeutics announces new data from COR-I, COR-II and COR-Diabetes trials for Contrave

Omega-3 fatty acid supplements do not improve levels of depression in heart disease patients

Supplemental oxygen during stroke is effective to combat brain tissue damage

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News